Albany NY, United States: Lipodystrophy is abnormal central fat accumulation or localized loss of fat tissue or mixed clinical presentations representing both.
Albany NY, United States: Lipodystrophy is abnormal central fat accumulation or localized loss of fat tissue or mixed clinical presentations representing both. It is also known as the Lawrence-Seip syndrome, a rare group of syndromes, either acquired or congenital. People with lipodystrophy experience an uncontrolled loss of fat tissue, especially fat under the skin. This causes a drop in an important hormone called leptin. Without enough fat tissue or Leptin, the body’s system for regulating energy use falls out of balance.
Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=47643
As per the Lipodystrophy United, the global prevalence of lipodystrophy has been estimated at less than 1 case in 100,000 people. According to an article published in the Journal of Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, in 2017 in Europe, the prevalence of lipodystrophy was 2.63 cases/million. The two most common acquired varieties of lipodystrophy include acquired generalized lipodystrophy and acquired partial lipodystrophy. Highly active antiretroviral therapy-induced lipodystrophy in HIV-infected patients and drug-induced localized lipodystrophy are other common sub-types. Lipodystrophy is a rare disease that affects fewer than 200,000 people in the U.S.. The global lipodystrophy treatment market is expected to expand at a robust pace during the forecast period. High return on investments for the development of orphan drugs, strong research and development initiatives for orphan drugs in developed countries, and increase in the number of rare diseases related to genetic mutations that are treated using orphan drugs are expected to drive the market in the coming years.
Request for Covid-19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=47643
The global lipodystrophy treatment market can be segmented based on disease, drug class, end-user, and region. Based on disease, the lipodystrophy treatment market can be divided into acquired generalized lipodystrophy and acquired partial lipodystrophy. Till now, there is no cure for lipodystrophy, and the effects of treatment vary from person to person. There is only one FDA-approved treatment for generalized lipodystrophy (myalept), and there are no approved treatments for partial lipodystrophy. In terms of end-user, the global lipodystrophy treatment market ca be segmented into academic & research institutes, hospital, and others. Increase in R&D in the health care sector, which utilizes gene sequencing for the testing of orphan diseases, is expected to drive the lipodystrophy treatment market during the forecast period.
High rate of growth of the lipodystrophy treatment market can be attributed to the entry of novel, expensive therapies and high unmet needs. More high-priced therapies are expected during the forecast period. Kalydeco for cystic fibrosis and exon-skipping therapies for Duchenne muscular dystrophy are new therapies introduced in the market. Competitive activity is increasing as larger companies realize the rewards of investing in orphan therapeutics. High unmet needs and low competition in several regions are expected to attract more companies to the market in the near future.
Enquiry Before Buying: https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=47643
Based on region, the lipodystrophy treatment market can be categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a major share of the lipodystrophy treatment market. According to a report of Research Office, Legislative Council Secretariat, there are between 25-30 million people suffering from rare diseases in the U.S.. Strong focus on research and development and government aids, such as research grants, tax credits, and fee waivers, to promote R&D contribute to the growth of the market. As a result, over 4,171 drugs have been designated the orphan drug status in the U.S. as of June 2017. In addition, favorable reimbursement offered by the government and private payers for the treatment of rare diseases drives the market in the region.
Europe is a prominent region of the orphan drugs market. According to a Research Office Legislative Council Secretariat report, in 2015, over 30 million people were suffering from rare diseases in the European Union. Incentives offered to promote the manufacture of orphan drugs in the region, such as a10-year period of marketing exclusivity, research grants, and reduced fees for marketing authorization applications, aid in the expansion of the market. Over 1,805 drugs have been granted orphan drug status in the European Union, and over 128 drugs were granted marketing authority from 2000 to 2016.
Players operating in the global market are Aegerion Pharmaceuticals, Inc. Akcea Therapeutics Inc, Ambrx, Inc., Amunix Operating Inc., Bolder Biotechnology, Inc., Theratechnologies Inc., GlaxoSmithKline plc, Novelion Therapeutics Inc., and Sun Pharmaceutical Industries Limited.
More Trending Reports by Transparency Market Research:
HIV-associated Lipodystrophy Market: Changes in body fat concentration, affecting people with HIV, is known as HIV-associated lipodystrophy. The exact causes of this condition is currently unknown, but research suggests that this disorder can occur either due to HIV infection or as a consequence of side effects associated with drugs used in HIV infection treatment, such as Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Protease Inhibitors (PIs), etc.
Prurigo Nodularis Treatment Market: The global prurigo nodularis treatment market is anticipated to gather pace in its growth due to the rarity of the disease. As per the findings of the National Institutes of Health (NIH), rare diseases are expected to increase in number at the rate of 250 per annum. However, only 5% of them have been dealt with until today.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/